Susquehanna International Group, LLP Humanigen, Inc Call Options Transaction History

Susquehanna International Group, LLP

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2022 Nov 14, 2022	SELL	$0.15 - $3.02 $27,540 - $554,472	-183,600 Reduced 91.12%	17,900 $3,000
Q2 2022 Aug 15, 2022	SELL	$1.76 - $3.33 $106,128 - $200,799	-60,300 Reduced 23.03%	201,500 $357,000
Q1 2022 May 16, 2022	BUY	$1.81 - $3.97 $281,093 - $616,541	155,300 Added 145.82%	261,800 $788,000
Q4 2021 Feb 14, 2022	BUY	$3.66 - $8.22 $204,594 - $459,498	55,900 Added 110.47%	106,500 $396,000
Q3 2021 Nov 15, 2021	SELL	$5.93 - $17.83 $421,623 - $1.27 Million	-71,100 Reduced 58.42%	50,600 $300,000
Q2 2021 Aug 11, 2021	SELL	$13.54 - $22.74 $2.93 Million - $4.93 Million	-216,700 Reduced 64.04%	121,700 $2.12 Million
Q1 2021 May 17, 2021	BUY	$12.91 - $23.83 $3.95 Million - $7.3 Million	306,200 Added 950.93%	338,400 $6.46 Million
Q4 2020 Feb 16, 2021	BUY	$7.97 - $21.66 $256,634 - $697,452	32,200 New	32,200 $564,000

558K

Ticker HGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,661,000
Description
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called ?cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.